Published on January 24, 2012 at 1:40 AM
The 30-day freedom from major adverse event rate (MAE) was 93.1 percent, with no death, amputation, pseudo-aneurysm, or clinically-driven target vessel revascularization; three distal embolizations occurred and all three were treated without clinical sequelae. The data demonstrated a low 30-day MAE rate, a low bail-out stent rate, and a high rate of successful revascularization.
P.A.D. is one of the most common vascular diseases and occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe leg pain for patients, limited physical mobility and non-healing leg ulcers. According to the American Heart Association, approximately 10 million people in the U.S. suffer from P.A.D.
"This study is just one aspect of the Covidien DEFINITIVE Trial Series, which is focused on demonstrating the efficacy of plaque excision as a safe and effective option in the treatment of P.A.D.," said Stacy Enxing Seng, President, Vascular Therapies, Covidien. "The results are promising in this large cohort of patients with advanced disease in challenging lesions."
Source: COVIDIEN